Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ProBioGen, Tizona Ink License and Manufacturing Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

ProBioGen, Tizona Ink License and Manufacturing Pact

Will apply GlymaxX cell line to boost anti-tumor activity of immuno-oncology antibody

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen  and Tizona Therapeutics have signed a commercial license and service agreement for cell line and process development. ProBioGen will develop Tizona’s immuno-oncology antibody up to GMP manufacturing, using its GlymaxX cell line to boost the antibody’s ADCC anti-tumor activity.
 
The program will follow ProBioGen’s development path, which, according to the company, allows selecting superior, stable producer clones with robust process features in reduced time, facilitating the earlier onset of clinical trials. ProBioGen will manufacture clinical materials at its new facility, which will house two additional 1,000L single-use bioreactors in its GMP suites.
 
Volker Sandig, ProBioGen’s chief scientific officer said, “We were impressed by the scientific approach and quality of work which Tizona has invested into this product candidate already, and we are looking forward to combining our expertise with that of Tizona for this very promising product candidate.”
 
Tizona’s chief operating officer, Jeremy Bender, said, “We were seeking a high quality service provider with a proven track record and a robust ADCC enhancement technology for our project, and ProBioGen’s package of technical and scientific expertise, timelines, financial terms and, importantly, people behind it, were a compelling combination.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics